OAM
CLLS

Oppenheimer Asset Management’s Cellectis CLLS Stock Holding History

Oppenheimer Asset Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-140
Closed -$4K – 1682
2017
Q2 		$4K Hold
140
– – ﹤0.01% 1571
2017
Q1 		$3K Buy
+140
New +$2.94K ﹤0.01% 1613

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Oppenheimer Asset Management's CLLS Position: Q3 2017 in Review

Oppenheimer Asset Management sold out of Cellectis (CLLS) in Q3 2017, closing a stake of 140 shares — an estimated $4K sold.

Oppenheimer Asset Management first reported a position in CLLS in Q1 2017 and held it in 2 quarters. The position peaked at $4K in Q2 2017. 42 funds tracked by Wall St. Rank hold CLLS as of Q3 2017.

  • Oppenheimer Asset Management reported no remaining Cellectis position as of Q3 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 140 Cellectis shares in Q3 2017, an estimated $4K.
  • Oppenheimer Asset Management first reported a position in Cellectis in Q1 2017 and held it in 2 quarters.
  • Oppenheimer Asset Management's Cellectis position peaked at $4K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Cellectis as of Q3 2017.

Based on Oppenheimer Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.